Vote Scores

Home / Companies / Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Company · votes reported on Form N-PXname as filed

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

How funds and institutional managers reported voting their shares, year to 30 June 2026

Filers reporting
11year to 30 June 2026
Against management on pay
n/ano say-on-pay item reported
Same, by reported shares
n/ashares reported on Form N-PX
Meetings on file
9across 3 seasons

foragainstabstain, withhold or otheramber tick: the portion cast against management

For the year to 30 June 2026, 11 funds and managers listed Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in their Form N-PX filings (2 meetings).

No say-on-pay item was reported for this company in the season, so there is no dissent figure to compare.

Meetings

Meeting dateSeasonFilers reportingItemsAgainst management on pay
15 May 2026year to 30 June 2026114not reported
15 Dec 2025year to 30 June 2026113not reported
9 Jun 2025year to 30 June 202581not reported
15 May 2025year to 30 June 202594not reported
30 Dec 2024year to 30 June 202594not reported
22 Nov 2024year to 30 June 202591not reported
29 Oct 2024year to 30 June 202592not reported
15 May 2024year to 30 June 202484not reported
28 Nov 2023year to 30 June 202472not reported

Meetings with 20 or more reporting filers have their own page with every item. Dates are as filers typed them; dates up to three days apart are treated as one meeting.

Say-on-pay: this company and the median

year to 30 June 2026Tianjin Pharmaceutical Da Ren Tang Group Corporation LimitedMedian company
Reporting filers voting against managementnot reported6.6%
Reported shares voted against managementnot reported2.9%

Among filers reporting on Form N-PX. The median is over 3,799 companies with a say-on-pay item reported by 20 or more filers.

How the largest families voted

Meeting of 15 Dec 2025: say-on-pay and each shareholder proposal that could be told apart.

None of the families tracked on this site reported a position on these items.

By season

SeasonFilers reportingAgainst management on pay, filersBy reported sharesSay-on-pay split
year to 30 June 20248not reportednot reported
year to 30 June 20259not reportednot reported
year to 30 June 202611not reportednot reported

Category mix

Share of the vote records reported for this company, by the category filers chose.

CategoryVote recordsShare
CORPORATE GOVERNANCE30430.6%
CAPITAL STRUCTURE24324.5%
COMPENSATION23223.4%
EXTRAORDINARY TRANSACTIONS838.4%
DIRECTOR ELECTIONS686.9%
AUDIT-RELATED626.3%

Questions

How did large funds vote at Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited?

11 filers reported votes at Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited for the year to 30 June 2026. The table on this page lists the position of each of the largest fund families.

Were there shareholder proposals at Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited?

No proposal from security holders was reported by enough filers to be shown for the year to 30 June 2026.

Is this the meeting result?

No. The figures are shares of the funds and managers that file Form N-PX, and of the shares they reported. Holders that do not file the form (individuals, most foreign investors, insiders) are not included, so the split here can differ widely from the certified result, which Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited reports on Form 8-K.

Where does the data come from?

From Form N-PX filings on the SEC's EDGAR system, grouped by company. Filers type company names and meeting dates themselves; this site groups spellings of the same company and folds meeting dates up to three days apart. Data runs through 30 Sep 2026; the median compares 3,799 companies.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, grouped by company. The name is the most common spelling among filers. Not verified by the SEC. Filings read through 30 Sep 2026; page built 1 Oct 2026.